Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis
Open accessThe DOI matches its Crossref record; 73 of the 73 references it cites were found in a registry or an index.
Abstract
Despite widespread use of statins to reduce low-density lipoprotein cholesterol (LDL-C) and associated atherosclerotic cardiovascular risk, many patients do not achieve sufficient LDL-C lowering due to muscle-related side effects, indicating novel treatment strategies are required. Bempedoic acid (ETC-1002) is a small molecule intended to lower LDL-C in hypercholesterolemic patients, and has been previously shown to modulate both ATP-citrate lyase (ACL) and AMP-activated protein kinase (AMPK) activity in rodents. However, its mechanism for LDL-C lowering, efficacy in models of atherosclerosis and relevance in humans are unknown. Here we show that ETC-1002 is a prodrug that requires activation by very long-chain acyl-CoA synthetase-1 (ACSVL1) to modulate both targets, and that inhibition of ACL leads to LDL receptor upregulation, decreased LDL-C and attenuation of atherosclerosis, independently of AMPK. Furthermore, we demonstrate that the absence of ACSVL1 in skeletal muscle provides a mechanistic basis for ETC-1002 to potentially avoid the myotoxicity associated with statin therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 ETC-1002-CoA inhibits ACL and mediates β1-selective AMPK activation. Recombinant human ACL was incubated in the presence of the indicated concentrations of ETC-1002-CoA (a–c) or ETC-1002 (d), and (a) coenzyme A (CoA), (b) citrate or (c) ATP. Conversion of [14C]-citrate to [14C]-acetyl-CoA was measured in counts per minute (CPM). Recombinant human (e) AMPKα1β1γ1 and (f) AMPKα1β2γ1 complexes were incubated in the presence of the indicated concentrations of ETC-1002, ETC-1002-CoA, AMP or A-769622. (g) Structure of ETC-1002 and the biochemical reaction that generates ETC-1002-CoA acyl-CoA synthetase (ACS). ETC-1002-CoA/CoASH enzyme ACL kinetic analyses are single measures, and representative results from n=3 independent experiments shown; AMPK activity was determined by time-resolved fluorescence resonance energy transfer expressed as mean±s.e.m. of triplicate measures. (a) Ki calculated by Michaelis–Menten kinetic analysis.](https://figures.cochat.ai/paper-figures/02df10a0267b44eda297dc9dcee13726/liver-specific-atp-citrate-lyase-inhibition-by-bempedoic-acid-decreases-ldl-c-figure-1.jpg)
![Figure 2 Differentiation of ETC-1002 from the myotoxic effects of statins. [14C]-ETC-1002 (10 μM) conversion to [14C]-ETC-1002-CoA in human liver microsomes was determined in the presence of 30 μM unlabelled (a) monocarboxylic and (b) dicarboxylic saturated competitive fatty acid substrates. RH7777 cells were treated with negative control (Control) or Slc27a2 (ACSVL1) siRNA; n=6, for 48 h, and (c) ACSVL1 expression determined by western blot, and [14C]-ETC-1002-CoA synthesis determined; n=3. (d) Both control and Slc27a2 siRNA-treated RH7777 cells were treated with vehicle, ETC-1002 (30 μM) or atorvastatin (0.5 μM), and de novo cholesterol synthesis measured over 4 h; n=6 transfections. (e) Relative ACSVL1 expression in microsomes prepared from human liver, kidney and skeletal muscle (SkM). (f) ETC-1002-CoA synthetase activity in microsomes prepared from human liver and skeletal muscle; palmitate (10 μM) used as a positive control for skeletal muscle microsome viability. (g) ACSVL1 expression was measured in primary human hepatocytes and primary human skeletal muscle (SkM) cells by western blotting and expressed relative to β-actin. (h) Primary human myotubes were treated with vehicle (Veh.), simvastatin 10 μM (Simva), atorvastatin 10 μM (Atorva) or ETC-1002 100 μM in the presence of [14C]-glucose for 12 h, and incorporation into non-saponifiable lipids determined; or treated with 0.1–100 μM simvastatin, atorvastatin or ETC-1002 for 48 h and (i) cytotoxicity was measure by GF-AFC/bis-AAF-R110 cleavage, and (j) Caspase 3,7 activity (DEVD cleavage) determined. Data for myotube cytotoxicity assays are expressed as mean±s.e.m., n=2 performed in triplicate. Data for liver (n=50 donors pooled) and kidney (n=50 donors pooled) microsome preparations are representative of two independent experiments performed in duplicate, and expressed as mean±s.d. Data for human skeletal muscle microsomes (n=4 pooled donors) are the mean±s.e.m. of two independent experiments performed in triplicate. Multiple comparisons were made using an one-way ANOVA, Bonferroni's multiple comparisons test; *P<0.05.](https://figures.cochat.ai/paper-figures/aa53cfde988849fa938e4aa3379a9671/liver-specific-atp-citrate-lyase-inhibition-by-bempedoic-acid-decreases-ldl-c-figure-2.jpg)


![Figure 5 ACL suppression increases LDLR. (a) Primary human hepatocytes were treated with vehicle or ETC-1002 (100 μM) for 18 h in the presence of [3H]-H2O or pretreated with the indicated concentrations of ETC-1002 for 1 h, following a 3 h [14C]-acetate pulse. Counts incorporated into the non-saponifiable (sterols), and saponifiable (fatty acids) lipid fractions were determined and expressed as % vehicle. (b) Primary human hepatocytes were treated with vehicle, atorvastatin (0.5 μM) or ETC-1002 (100 μM) for 36 h and total intracellular cholesterol concentrations were determined in cell lysates. (c) Media was assayed for apoB by enzyme-linked immunosorbent assay. (d) PHHs were treated with ETC-1002 for the indicated time points and the apoB concentrations were measured in the media. (e) PHH were pre-labelled overnight with [14C]-oleate and the effects of ETC-1002 treatment on oleate-derived counts in the media determined at the indicated time points. PHH hepatocytes were treated with ETC-1002 and atorvastatin, and (f) mRNA levels for HMGR, SREBF2, PCSK9 and LDLR were determined by reverse transcription–quantitative PCR or (g) LDL receptor activity determined; A-769662 (10 μM). (h) RH7777 cells were treated with the indicated concentrations of ETC-1002 or atorvastatin (0.5 μM), and [14C]-lactate incorporation into cholesterol (Chol), cholesteryl esters (CE) and triglycerides determined. (i) LDLR-mediated DiI–LDL uptake in response to the indicated concentrations of ETC-1002±atorvastatin (0.5 μM). RH7777 cells were subjected to negative control (NC) or Acly siRNA-mediated gene silencing (n=3) and analysed for (j) ACL LDLR protein levels, or (k) LDLR-mediated DiI–LDL uptake. Data for PHH are expressed as mean±s.e.m. of n=2 donors performed in triplicate (a–c,f,g; except A-769662 treatment was 1 donor) or representative of two independent experiments showing similar results (d,e). (h) IC50 and (i) EC50 determinations were made using nonlinear curve fit model. Multiple comparisons were made using (a,j,k) unpaired Student's t-test or (b,c,f,g) an one-way ANOVA, Bonferroni's multiple comparisons test; *P<0.05.](https://figures.cochat.ai/paper-figures/bdd7bd8103b34bfd9b8c72b35fad6960/liver-specific-atp-citrate-lyase-inhibition-by-bempedoic-acid-decreases-ldl-c-figure-5.jpg)

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Bempedoic acid is a pro-drug that reduces cholesterol synthesis by inhibiting adenosine triphosphate (ATP) citrate lyase, with very limited musculoskeletal-related side effects.280”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [280]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A SIMPLE METHOD FOR THE ISOLATION AND PURIFICATION OF TOTAL LIPIDES FROM ANIMAL TISSUES
Folch, J., Lees, M., & Stanley, G. H. S. (1957) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)64849-5 · Cited by 65,189
Repertoires of Autophagy in the Pathogenesis of Ocular Diseases
Li, Y.-J., Jiang, Q., Cao, G.-F., Yao, J., & Yan, B. (2015) · Cellular Physiology and Biochemistry · doi:10.1159/000373980 · Cited by 16,304
Arzneimittelforschung: Erstanwendung am Menschen in der Phase I
Miletzki, B., & Gleiter, C. H. (2005) · Bundesgesundheitsblatt Gesundheitsforsch.Gesundheitsschutz · doi:10.1007/s00103-005-1024-7 · Cited by 9,355
Stone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., Goldberg, A. C., Gordon, D., Levy, D., Lloyd-Jones, D. M., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437738.63853.7a · Cited by 7,081 · cited 1×
“Triacsin C is a potent inhibitor of ACSL1 and 4, and a weak inhibitor of ACSVL1 (refs 43–47).”
Cholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
Cannon, C. P., Blazing, M. A., Giugliano, R. P., McCagg, A., White, J. A., Theroux, P., Darius, H., Lewis, B. S., Ophuis, T. O., Jukema, J. W., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1410489 · Cited by 4,487
Brown, M. S., & Goldstein, J. L. (1997) · Cell · doi:10.1016/s0092-8674(00)80213-5 · Cited by 3,834 · cited 1×
“Upregulation of the LDL receptor results in a new homeostatic state, where more cellular cholesterol is derived from blood LDL particles, thus reducing blood LDL-C 51–53 .”
The AMPK signalling pathway coordinates cell growth, autophagy and metabolism
Mihaylova, M. M., & Shaw, R. J. (2011) · Nature Cell Biology · doi:10.1038/ncb2329 · Cited by 2,923
Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events
Robinson, J. G., Farnier, M., Krempf, M., Bergeron, J., Luc, G., Averna, M., Stroes, E. S., Langslet, G., Raal, F. J., El Shahawy, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501031 · Cited by 2,296
Cited by
Items 401–499 of 499
Thompson, P. D. (2020) · Contemporary cardiology · doi:10.1007/978-3-030-33304-1_9
Mechanisms By Which Glucose Lowering Therapies Reduce Obesity And Atherosclerosis
Day, E. A. (2020) · MacSphere (McMaster University) · doi:10.71548/25269
Self-citationChallenges in constructing genetic instruments for pharmacologic therapiesPreprint
Ference, B. A., Smith, G. D., Holmes, M. V., Catapano, A. L., Ray, K. K., & Nicholls, S. J. (2020) · arXiv (Cornell University) · doi:10.48550/arxiv.2007.13115 · Cited by 1
“ATP citrate lyase (ACL) is an enzyme located upstream to HMG-CoA reductase in the cholesterol biosynthesis pathway.(12) Inhibiting ACL with bempedoic acid has been shown to reduce plasma LDL-C in several early phase randomized clinical trials.”
BackgroundBempedoic acid: A new player in lipid-lowering therapies
Cuevas, A. M., & Rodrigo Alonso, K. (2020) · Journal of clinical lipidology · doi:10.1016/j.jacl.2020.08.014
Sinning, D., & Landmesser, U. (2021) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/a-1199-8496
“[28] Pinkosky SL, Newton RS, Day EA et al.”
BackgroundBempedoinsäure – ein neuer Spieler in der Lipidtherapie
Eggebrecht, H. (2021) · Der Kardiologe · doi:10.1007/s12181-021-00447-y
Effects of Adipokine Retnla on the Regulation of High-Density Lipoprotein Metabolism
Lee, M. (2016) · Journal of the Korea Society of Computer and Information · doi:10.9708/jksci.2016.21.12.139
“도 지단백질과 저밀도 지단백질은 콜레스테롤을 동맥혈관 벽으로 수송하여 동맥벽에 콜레스테롤을 침착시키므로 동맥경화를 유발 하는 작용을 하는 반면[5], 고밀도 지단백질은 동맥벽에 쌓인 콜 레스테롤을 다시 간으로 수송하여 혈관을 깨끗하게 해 주므로 동 맥경화를 억제하는 작용을 한다[2].”
General Perspectives for the Treatment of Atherosclerosis
Gülcan, H. O., & Orhan, İ. E. (2020) · Letters in Drug Design & Discovery · doi:10.2174/1570180817999201016154400
Desarrollo clínico de ácido bempedoico: estudios fase 2 y fase 3
Lekuona, I., & Pintó, X. (2021) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2021.02.005 · Cited by 1
Bempedoic Acid: A First-in-Class Agent for Lowering Cholesterol Levels
McGraw-Senat, C. M., Dillard, N., Guelda, T., Samuel, E., & Ling, H. (2021) · The Senior Care Pharmacist · doi:10.4140/tcp.n.2021.331
Bempedoic acid: LDL-C lowering without adverse reactions
Whitney, K. R. (2021) · JAAPA · doi:10.1097/01.jaa.0000795036.55877.c8
De toepasbaarheid van de SUR-meting voor ultrafiltratie van rwzi-effluent
Janssen, A. N., & van der Graaf, J. H. J. M. (2012) · Research Repository (Delft University of Technology)
Lipidmanagement: Vor- und Nachteile der neuen Substanzgruppen
Hollstein, T. (2021) · Deutsches Ärzteblatt · doi:10.3238/persdia.2021.05.17.04
Kosten-Nutzen-Analyse neuer Lipidsenker
Blaum, C. M., Arnold, N., & Waldeyer, C. (2022) · Herz · doi:10.1007/s00059-022-05116-8
“Bempedoinsäure Bempedoinsäure ist ein oraler Lipidsenker aus der neuen Substanzklasse der ATP-Citrat-Lyase-Hemmer [38].”
BackgroundInfluentialXiong, J., Zhou, P., Jiang, H., Huang, T., He, Y., Zhao, Z., Zang, Y., Choo, Y., Wang, X., Chittiboyina, A. G., et al. (2021) · Angewandte Chemie · doi:10.1002/ange.202109082
Statine und neue Therapieoptionen zur Behandlung der LDL-Hypercholesterinämie
Katzmann, J. L., & Laufs, U. (2020) · Diabetes aktuell · doi:10.1055/a-1237-0720
“[11] Pinkosky SL, Newton RS, Day EA et al.”
BackgroundProgress in research of lipogenesis inhibitors for treatment of nonalcoholic fatty liver disease
Yang, L., Li, J.-Z., & Li, M. (2022) · World Chinese Journal of Digestology · doi:10.11569/wcjd.v30.i16.735
The role of fatty acids metabolism on cancer progression and therapeutics development
Moreira-Barbosa, C., Matos, A., Fernandes, R., Mendes-Ferreira, M., Rodrigues, R. C., Cruz, T., Costa, Â. M., Cardoso, A. P., Ghilardi, C., Oliveira, M. J., et al. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-824043-4.00007-5 · Cited by 1
Klose, G., Gouni‐Berthold, I., & März, W. (2022) · Journal für Klinische Endokrinologie und Stoffwechsel · doi:10.1007/s41969-022-00178-9
Romandini, A., Baldassarre, D., Genovese, S., Capri, S., Pompilio, G., Scatigna, M., & Werba, J. P. (2023) · Pharmaceuticals · doi:10.3390/ph16020176
“It is reported that, thanks to this mechanism, BA does not lead to clinically meaningful muscle-related symptoms and is, therefore, depicted as a kind of “muscle-sparing” statin equivalent [16].”
BackgroundGoldberg, A. C., Banach, M., Catapano, A. L., Duell, P. B., Leiter, L. A., Hanselman, J. C., Lei, L., & Mancini, G. B. J. (2023) · medRxiv · doi:10.1101/2023.02.14.23285912
Catapano, A. L. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-88286-6.00022-4
Coronel, L., Miguel, M. I., Blasi, J., Marsal, S., D’Agostino, M. A., & Möller, I. (2023) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2023-eular.3169 · Cited by 1
Emerging Lipoprotein-Related Therapeutics for Patients with Diabetes
Bobik, A., Cohen, N. D., Jenkins, A. J., Kyaw, T. S., SULLIVAN, D. R., Wu, X., Yu, X.-Y., & Little, P. J. (2023) · Contemporary diabetes · doi:10.1007/978-3-031-26681-2_30
Bempedoic acid as treatment for subjects at cardiovascular risk who are statin-intolerant
Doggrell, S. A. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2242259
“A higher reduction with bempedoic acid 120 mg in LDL cholesterol was subsequently reported, 43%, in subjects with elevated LDL cholesterol and diabetes [5].”
BackgroundNovel therapies in clinical use for the management of hyperlipidaemia
Mettananda, C. D. (2023) · Asian Journal of Internal Medicine · doi:10.4038/ajim.v2i2.105
Efficacy and Safety of Bempedoic Acid in Patients with High Cardiovascular Risk: An Update
Çaklılı, Ö. T., Rizzo, M., & Cesur, M. (2024) · Current Vascular Pharmacology · doi:10.2174/0115701611290763240126045433
Treatment of dyslipidemia in acute coronary syndrome
Yadav, S., & Sawhney, J. P. S. (2024) · Indian Heart Journal · doi:10.1016/j.ihj.2024.01.011 · Cited by 3
“81 85 In a recently published double-blind placebo-controlled RCT (CLEAR OUTCOMES)which included 13970 patients with a follow-up of ~40 months.”
BackgroundBos, M. M., Goulding, N., Lee, M. A., Hofman, A., Bot, M., Pool, R., Vijfhuizen, L. S., Zhang, X., Li, C., Mustafa, R., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14234926
PORTO, C. H. V., Gomes, J. P. P., Filho, A. M. M. D. S., Gomes, L. V. D. O., SOARES, C. V. S., Novais, A. K. R., Silva, D. I. D., Marinho, C. D. S., & de Oliveira, J. F. (2024) · doi:10.22533/at.ed.5122405043
Farmácia: fronteiras na pesquisa e desenvolvimento 3
Tescarollo, I. L. (2024) · doi:10.22533/at.ed.512240504
Rodrigues, M. V. B., Brandão, S. C., Papaya, E. U., Santos, I. S., Orué, S. L., Ferreira, I. C., Leite, D. F., da Rocha, P. D. S., Campos, J. F., dos Santos, E. L., et al. (2024) · doi:10.22533/at.ed.5122405041
PRINCIPAIS INTERAÇÕES COM ANTIBIÓTICOS
de Moura, J. J. D. M., & Cimatti, H. M. B. (2024) · doi:10.22533/at.ed.5122405045
FÁRMACOS UTILIZADOS NO TRATAMENTO DA HIPERCOLESTEROLEMIA
Navarro, L. T., & Twerdochlib, A. L. (2024) · doi:10.22533/at.ed.5122405044
Focused Cardiovascular Risk Assessment and Approaches in Men
Cheung, B., Faruque, S. C., Kim, K., Lam, S., Faaborg-Andersen, C. C., McLaughlin, T. J., Sperling, L. S., & Eapen, D. J. (2024) · Springer eBooks · doi:10.1007/978-3-031-53705-9_19
Cholesin and GPR146 in Modulating Cholesterol Biosynthesis
Kim, J., & Kim, Y. J. (2024) · Pharmacology · doi:10.1159/000540351 · Cited by 1
“To enhance LDL-C reduction in those who do not respond adequately to statins, additional treatments such as ezetimibe or bempedoic acid are utilized as adjunct therapies [28, 29].”
Expertenkonsens, V. V. P. E. G. F. D. K. L. B.-W. (2024) · Aktuelle Kardiologie · doi:10.1055/a-2287-2919
Novel approaches to treat primary hyperlipidemia
Vachhani, J. M., & Tirgar, P. (2024) · American Journal of Biopharmacy and Pharmaceutical Sciences · doi:10.25259/ajbps_7_2024
Использование бемпедоевой кислоты в клинической практике
Курочкина, Н. С., Зубарева, М. Ю., Р., А. А., & Владимирович, С. И. (2024) · Атеросклероз и дислипидемии · doi:10.34687/2219-8202.jad.2024.03.0002
Aragona, C. O., Bianco, A., Caruso, R., Cerulli, M., Cosentino, N., Cittadini, A., Gabriele, M., Mallardo, M., Marini, R., Miserrafiti, B., et al. (2024) · Monaldi Archives for Chest Disease · doi:10.4081/monaldi.2024.2972 · Cited by 1
Liebl, M., Olander, F., & Müller, C. (2025) · Archiv der Pharmazie · doi:10.1002/ardp.202400807
Bempedoic acid - a practical review
Nussbaumerová, B. (2025) · Vnitřní lékařství · doi:10.36290/vnl.2025.020
Use of bempedoic acid in an out-patient setting: an assessment of efficacy heterogeneityPreprint
Maarouf, A., Shergill, M. K., Jones, A. F., Marriott, J. F., & Ramachandran, S. (2025) · Research Square · doi:10.21203/rs.3.rs-6727985/v1
Sun, L., Liu, Y., Sun, Y., Huang, X., & Wang, G. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5361001
Арманович, А. А., Kaktursky, L. V., Urazova, O. I., Трофименко, А. И., Sukiasyan, L. M., Коган, Е. А., Демура, Т. А., & Вачиковна, П. Н. (2025) · Bulletin of Siberian Medicine · doi:10.20538/1682-0363-2025-2-124-140 · Cited by 1
Puertas-Umbert, L., Alonso, J., Blanco-Casoliva, L., Bentanachs, R., Asmarats, L., Arderiu, G., Martínez‐González, J., & Rodríguez, C. (2025) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2025.500856
Lack of impact of adjunctive lipid-modifying therapy in the CLEAR Outcomes trial
Menon, V., Bloedon, L. T., Li, N., Lincoff, A. M., Nicholls, S. J., Powell, H. A., & Nissen, S. E. (2025) · Journal of clinical lipidology · doi:10.1016/j.jacl.2025.10.072
Bouillet, B., Boulestreau, R., Aboyans, V., Béliard, S., Boccara, F., Cariou, B., Charrière, S., Moulin, P., Vergès, B. L., Valéro, R., et al. (2025) · Annales d Endocrinologie · doi:10.1016/j.ando.2025.102471
Prodrugs as drug delivery systems
Zhang, W. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-23521-4.00005-9
Zhao, X., Ma, X., Luo, X., Shi, Z., Deng, Z., Jin, Y., Xiao, Z., Tan, L., Liu, P., Jiang, S., et al. (2020) · Figshare · doi:10.6084/m9.figshare.13336387
Zhao, X., Ma, X., Luo, X., Shi, Z., Deng, Z., Jin, Y., Xiao, Z., Tan, L., Liu, P., Jiang, S., et al. (2020) · Figshare · doi:10.6084/m9.figshare.13336375
Zhao, X., Ma, X., Luo, X., Shi, Z., Deng, Z., Jin, Y., Xiao, Z., Tan, L., Liu, P., Jiang, S., et al. (2020) · Figshare · doi:10.6084/m9.figshare.13336381
Bos, M. M., Goulding, N., Lee, M. A., Hofman, A., Bot, M., Pool, R., Vijfhuizen, L. S., Zhang, X., Li, C., Mustafa, R., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14234932
You, J., Jin, Y., & Zhang, C.-Y. (2025) · Journal of Natural Medicines · doi:10.1007/s11418-025-01996-2
“Its central role in fueling pathways dysregulated in cancer, dyslipidemia, and hepatic steatosis has established ACLY as a validated therapeutic target [9], as evidenced by the clinical approval of Bempedoic Acid [ 10 ].”
Repositioning ACLY in liver cancer: from metabolic enzyme to a regulator of antitumor immunity
Zhao, S., Tang, J., & Xue, J. (2026) · Science China Life Sciences · doi:10.1007/s11427-025-3179-x
Gupta, G., Sindhu, S., Jain, A., Rajan, K., Hyanki, C., Bhandari, M., Pradhan, A. K., Kumar, R., & Dixit, R. K. (2026) · Indian Journal of Physiology and Pharmacology · doi:10.25259/ijpp_543_2025
Zhu, B., Ma, Y., Shao, Q., Cui, J., & Zhenyan, F. (2026) · Medicine · doi:10.1097/md.0000000000047898 · Cited by 1
“[6,13,14] Furthermore, tendon-related adverse reactions showed prominent positive signals, including tendon rupture, tendon pain, tendonitis, tendinopathy, tendon injury, and tendon discomfort.”
Effect of Lipid Management on Coronary Heart Disease Risk in Persons With Type 2 Diabetes
Brandts, J., & Ray, K. K. (2026) · Elsevier eBooks · doi:10.1016/b978-0-323-87862-3.00019-7
Evaluation of bempedoic acid in elderly patients: real-world evidence from the REALIST study
Muscoli, S., Marco, E. D., Puttini, F., Ghezzi, S. S., Ifrim, M., Amtaeh, M., Renga, E. M., Cappello, C. M., Barone, G., Chiricolo, G., et al. (2026) · Frontiers in Aging · doi:10.3389/fragi.2026.1675989 · Cited by 1
“In addition, BA has been shown to significantly reduce levels of high-sensitivity C-reactive protein (hs-CRP), an important marker of systemic inflammation that is particularly important in older patients with chronic, low-grade inflammation and increased CV risk (Pinkosky et al., 2016).”
Puertas-Umbert, L., Alonso, J., Blanco-Casoliva, L., Bentanachs, R., Asmarats, L., Arderiu, G., Martínez-González, J., & Rodriguez, C. R. (2026) · Clínica e Investigación en Arteriosclerosis (English Edition) · doi:10.1016/j.artere.2026.500856
Novokhatskaya, E. A., Ershova, A. I., & Drapkina, O. M. (2026) · CARDIOVASCULAR THERAPY AND PREVENTION · doi:10.15829/1728-8800-2026-4742
Zingano, C. P., Brennan, D. M., Bloedon, L. T., Li, N., Herout, P. M., Powell, H. A., Spiazzi, B. F., Ray, K. K., Nicholls, S. J., Nissen, S. E., et al. (2026) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwag195 · Cited by 1
Mechanism of ACLY in Glucose and Lipid Metabolism
袁, 乐. (2026) · Advances in Clinical Medicine · doi:10.12677/acm.2026.1641524
Alabrahim, O. A. A., & Allam, N. K. (2026) · Inflammation and Regeneration · doi:10.1186/s41232-026-00413-9
From Single-target to System Remodeling:Combination Therapeutic Strategies for Metabolic Diseases
Xie, Z., & Li, J. (2026) · 中国科学基金 · doi:10.3724/bnsfc-2025-0006
“…[ 42 ] 。此外 , 针对胆固 醇合成上游的 ATP 依赖的柠檬酸裂解酶 ( ATP-Citrate Lyase , ACLY ) 抑制剂 ( 如 Bempedoic Acid ) 与依折麦布的 组合也已获批上市 , 为他汀不耐受或高危人群提供更细 化的分层治疗选择 [ 43 , 44 ] 。而此类二羧酸类 ACLY 抑制 剂也可以通过激动 PAPRα , 多机制改善 MASH [ 45-47 ] 著降低复发性心血管事件发生概率 [ 48 ] 。此外 , 低剂量秋 水仙碱作为非选择性炎症抑制剂也显示出显著减少慢性 冠心病患者心血管事件的效果 [ 49 ]…”
Wu, Y., Yeh, C., Hsu, C.-Y., Lin, C. Y., Huang, C., Tang, S., Huang, Y. T., Lin, C. Y., Yu, C.-H., Huang, C. Y., et al. (2026) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2026.04.111 · Cited by 1
Chinese expert consensus on the choice of initial cholesterol-lowering strategy
Wu, N., Wang, X., Ye, P., Chen, H., Chen, Z., Zhao, D., Dq, P., Guo, Y., Gao, Y., Yang, J.-G., et al. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1798787
“Since it is not metabolized into active products in skeletal muscle, bempedoic acid may avoid the skeletal muscle-related adverse effects associated with statin therapy (Pinkosky et al., 2016).”
Kitamoto, R., Isogai, Y., & Shimano, H. (2026) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.66057
“…well-known feedback mechanism of HMG-CoA reductase inhibition, AC L inhibition suppresses the cholesterol biosynthesis pathway, leading to increased density and activity of hepatic LDLR, enhanced clearance of LDL particles from the bloodstream, and a reduction in serum LDL-C levels 11) (Fig.1A) .”
Alaspure, A. C., Yadav, A. D., Lodha, S. R., Gore, A. H., Kalyankar, G. G., & Patole, S. P. (2026) · Arabian Journal of Chemistry · doi:10.25259/ajc_360_2025
Zhang, X., Gao, S., Chen, D., Wang, H., Zuo, M., Wang, L., Zhang, Q., & Wang, R. (2026) · Biomaterials · doi:10.1016/j.biomaterials.2026.124333
Patel, N. C., Bhosale, S., Patel, K., Tiwari, K. N., & Yadav, J. S. (2026) · ChemistrySelect · doi:10.1002/slct.73562
Alaspure, A. C., Yadav, A. D., Lodha, S. R., Gore, A. H., Nilewar, S. S., Harde, M. T., Patole, S., & Gorde, P. L. (2026) · Journal of Liquid Chromatography & Related Technologies · doi:10.1080/10826076.2026.2685477
“By inhibiting ACL, BMA effectively reduces cholesterol production in the liver [5].”
Beyond nutrition: lipids-based therapeutics from food and bioactive lipids
Kralovec, J. A. (2026) · Journal of Food Bioactives · doi:10.26599/jfb.2026.95034443
Minutolo, R., Nicola, L. D., Cesaro, A., Cozzolino, M. G., Lullo, L. D., Iacoviello, M., Paoletti, E., Ravera, M., & Russo, V. (2026) · Current Atherosclerosis Reports · doi:10.1007/s11883-026-01434-y · Cited by 1
“Bempedoic acid lowers LDL-C levels similarly to statins by reducing hepatic cholesterol synthesis and raising LDL receptor expression [43].”
Crosstalk Between Immunometabolic Pathways in Non-Small Cell Lung Cancer
Khilwani, R., Gulhane, P., Tukrul, M., Rani, D., Kumar, G., Goswami, S., & Singh, S. (2026) · Immunological Investigations · doi:10.1080/08820139.2026.2698754
“Targeting this protein helps in reversing the acidic and immunosuppressive environment (Pinkosky et al., 2016).”
Kronenberg, F., Höllerl, F., Brath, H., Rega‐Kaun, G., Greber‐Platzer, S., Weiser, C., Klein, D. P., Riesenhuber, N., Binder, C. J., Brix, J. M., et al. (2026) · Wiener klinische Wochenschrift · doi:10.1007/s00508-026-02760-6
Duan, Y., Gong, K., & Wang, D. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-34186-1.01002-1
Danalou, N. S., Dikmen, K., Konaç, E., Canbolat, O., & Kavutçu, M. (2026) · Molecular Biology Reports · doi:10.1007/s11033-026-12531-1
“Pharmacological inhibition of ACLY has attracted attention in cancer metabolism, and preclinical and translational studies have shown that ACLY inhibitors can limit tumor growth by suppressing lipid synthesis [7, 40 – 42].”
Gómez-Barrado, J., Gómez-Turégano, P., Turégano-Yedro, M., Jiménez-Baena, E., Fernández-Chamorro, A. I., & Gómez-Turégano, M. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15156102
“Bempedoic acid (BA) is an oral prodrug that inhibits ATP citrate lyase (ACLY), a key enzyme upstream of HMG-CoA reductase, thereby reducing hepatic cholesterol synthesis and increasing LDL receptor expression [8,9].”
Prodrug Strategies in Atherosclerosis: Targeted Delivery and Therapeutic Advances
Mirhadi, E., Almahmeed, W. A., Kesharwani, P., & Sahebkar, A. (2026) · Cardiovascular Therapeutics · doi:10.1155/cdr/5159097
“In mice deficient for both ApoE and AMPK β 1, administration of ETC-1002 led to a marked reduction in hepatic cholesterol and triglyceride levels, downregulated lipogenic activity, and mitigated the progression of atherosclerotic lesions through mechanisms independent of AMPK signaling [85].”
Sarti, A., Sciaramenti, G., Camaiti, G., Cioci, P., Rizza, C., Tezze, R., Vocale, L. R., Hoxha, K., Maccaferri, I., Paparazzo, F., et al. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15166358
“By inhibiting ATP citrate lyase, an enzyme acting upstream of HMG-CoA reductase in the cholesterol biosynthetic pathway, bempedoic acid increases LDL receptor expression and enhances LDL particle clearance from the circulation [25].”
Cardiovascular Risk Factors in Youth
Khoury, M., & Urbina, E. M. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-11851-7.00015-x
Garg, N., Jaiswal, A., Kapoor, A., Tewari, S., Khanna, R., Sahu, A., Katheria, A., Nazir, A., & Jaiswal, A. (2026) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2026.08.009
ATP Citrate Lyase in Metabolic Disease: Mechanistic Insights and Clinical Potential
Wang, W., Li, X., Shi, H., Song, G., Xie, Z., & Li, J. (2026) · iNew Medicine · doi:10.1002/inm3.70077
Epigenomic Remodeling by Lipid Metabolism: A Cross-Disease Perspective on Cancer and Brain Disorders
Rafique, A., Farooq, A., Cho, C. E., & Bakovic, M. (2026) · Genes · doi:10.3390/genes17091134
Current, novel and emerging lipid-lowering therapies in pediatric familial hypercholesterolemia
Houter, E., van den Bosch, S. E., Hutten, B. A., & Corpeleijn, W. E. (2026) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000001060 · Cited by 1
Haberbosch, L., Baessler, A., de Ruiter, U., Sinning, D., Katzmann, J. L., Könemann, S., Schatz, U., Mai, K., Kassner, U., & Bobbert, T. (2026) · Lipids in Health and Disease · doi:10.1186/s12944-026-03062-6
“Bempedoic acid is a first-in-class adenosine triphosphate citrate lyase inhibitor [10], and has demonstrated efficacy in reducing LDL-C levels and the risk of CV events in the CLEAR clinical trial programme [11–14].”
Bempedoic Acid: From Guidelines to the Real World
Zimodro, J. M., & Gouni‐Berthold, I. (2026) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2026.15.3.381 · Cited by 1
“35-37 Genetic variants mimicking ACL inhibition were associated with lower LDL-C levels and lower CVD risk.”
Hu, S., Guo, Z., Li, C., Nie, X., Wang, J., He, J., Zhuang, C., Zhang, L., Li, D., Lin, Y., et al. (2026) · Cardiovascular Innovations and Applications · doi:10.15212/cvia.2026.0011
Chin, A. L., & O’Connell, J. B. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-28432-8.00012-0
Huang, C., Wu, H., Zhang, S., Feng, W., Liu, Z., Hua, C., Chen, D., Han, G., Gao, Y., 张恒辉, et al. (2026) · Phytomedicine · doi:10.1016/j.phymed.2026.158846
Pattabiraman, N., Lobello, C., Rushmore, D., Wang, S., Mologni, L., Borgh, H., Nath, K., Zhang, W., Goldman, A. R., Nejati, R., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.09.29.755331
Research progress on ATP-citrate lyase and its inhibitors: a metabolic-epigenetic perspective
Liu, Q., Sun, H., & Dai, L. (2026) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2026.2744392
“…statin therapy 63 . the key cleAR Outcomes trial (Nct02993406; n = 13,970) showed that compound 13 treatment significantly reduced lDl-c levels (by 21.1% versus placebo) after 6 months in statin-intolerant patients with hypercholesterolemia 63 . in Phase iii trials such as cleAR 49,112 ,115–118 .”
InfluentialValle, C. D., Zuin, M., & Bilato, C. (2026) · European Journal of Clinical Investigation · doi:10.1111/eci.70267
“BA is a prodrug that is activated primarily in the liver by very long-chain acyl-CoA synthetase 1, which is not expressed in skeletal muscle [45].”
The AMPK signaling pathway in cell metabolism and human diseases
Zhang, Z., Gu, Y., He, H., Qiao, S., Shao, Y., 龙先铭, Huang, J., Zhang, L., & Zhou, F. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-02790-6
Metadata
- Authors
- Pinkosky, S. L., Newton, R. S., Day, E. A., Ford, R. J., Lhotak, S., Austin, R. C., Birch, C. M., Smith, B. K., Filippov, S., Groot, P. H. E., Steinberg, G. R., & Lalwani, N. D.
- Affiliations
- Esperion Therapeutics (United States) (US)
- McMaster University (CA)
- St. Joseph’s Healthcare Hamilton (CA)
- Corresponding author
- Pinkosky, Stephen L.
- Steinberg, Gregory R.
- Venue
- Nature Communications
- Published
- 2016-11-28
- Volume
- 7
- Issue
- 1
- Pages
- 13457-13457
- ISSN
- 2041-1723 (ISSN-L)
- PMC
- PMC5133702
- OpenAlex
- W2558991743
- Cited by
- 498
- References
- 73
- Citations by year
- 2026: 63 · 2025: 50 · 2024: 76 · 2023: 79 · 2022: 55 · 2021: 67 · 2020: 50 · 2019: 24 · 2018: 21 · 2017: 10 · 2016: 1
- FWCI
- 21.05
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Nature Communications (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Minerva Access (University of Melbourne) (submittedVersion, cc-by)
- Funders
- Amgen
- Heart and Stroke Foundation of Canada
- McMaster University
- Esperion Therapeutics
- Amgen Canada
- Canadian Institutes of Health Research
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
- Keywords
- bempedoic acid, ATP citrate lyase, LDL cholesterol lowering, atherosclerosis, prodrug activation, LDL receptor upregulation, AMPK, hypercholesterolemia, skeletal muscle
- MeSH terms
- Adenylate Kinase, Animals, ATP Citrate (pro-S)-Lyase, Dicarboxylic Acids, Enzyme Activation, Enzyme Inhibitors, Fatty Acids, Humans, Cholesterol, LDL, Liver, Mice, Inbred C57BL, Models, Biological, Organ Specificity, Receptors, LDL, Up-Regulation, Mice, Knockout, Disease Progression, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Hepatocytes, Atherosclerosis, Lipid Metabolism
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.